PE20240806A1 - Composicion y metodos para el tratamiento de la enfermedad de fabry - Google Patents

Composicion y metodos para el tratamiento de la enfermedad de fabry

Info

Publication number
PE20240806A1
PE20240806A1 PE2023002431A PE2023002431A PE20240806A1 PE 20240806 A1 PE20240806 A1 PE 20240806A1 PE 2023002431 A PE2023002431 A PE 2023002431A PE 2023002431 A PE2023002431 A PE 2023002431A PE 20240806 A1 PE20240806 A1 PE 20240806A1
Authority
PE
Peru
Prior art keywords
fabry disease
treatment
composition
methods
refers
Prior art date
Application number
PE2023002431A
Other languages
English (en)
Inventor
Rizwana Islam
Mugdha Ravindra Deshpande
Madhusudan Natarajan
Yung Hee Park
Vivian Choi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20240806A1 publication Critical patent/PE20240806A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a un vector de dependoparvovirus recombinante (rAAV) empaquetado en una capside de AAV de amplio tropismo tisular, donde dicho vector comprende: a. una repeticion de terminal invertida (ITR) en 5'; b. un promotor ubicuo; c. una secuencia de nucleotidos que codifica la enzima alfa-GAL; d. un poli A; y e. una ITR en 3'. Tambien se refiere a un metodo para tratar la enfermedad de Fabry en donde se administra dicho vector rAAV empaquetado en una capside de AAV.
PE2023002431A 2021-02-26 2022-02-25 Composicion y metodos para el tratamiento de la enfermedad de fabry PE20240806A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163154485P 2021-02-26 2021-02-26
PCT/US2022/017998 WO2022183052A1 (en) 2021-02-26 2022-02-25 Composition and methods for the treatment of fabry disease

Publications (1)

Publication Number Publication Date
PE20240806A1 true PE20240806A1 (es) 2024-04-18

Family

ID=80786597

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002431A PE20240806A1 (es) 2021-02-26 2022-02-25 Composicion y metodos para el tratamiento de la enfermedad de fabry

Country Status (17)

Country Link
US (1) US20240175054A1 (es)
EP (1) EP4298227A1 (es)
JP (1) JP2024509792A (es)
KR (1) KR20230150836A (es)
CN (1) CN117321212A (es)
AR (1) AR124981A1 (es)
AU (1) AU2022227017A1 (es)
BR (1) BR112023016983A2 (es)
CA (1) CA3209673A1 (es)
CL (1) CL2023002530A1 (es)
CO (1) CO2023011012A2 (es)
EC (1) ECSP23072174A (es)
IL (1) IL305440A (es)
MX (1) MX2023009978A (es)
PE (1) PE20240806A1 (es)
TW (1) TW202302855A (es)
WO (1) WO2022183052A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024042485A1 (en) * 2022-08-25 2024-02-29 Takeda Pharmaceutical Company Limited Composition for use in the treatment of fabry disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
CA2287478C (en) 1997-04-14 2007-06-19 Richard J. Samulski Methods for increasing the efficiency of recombinant aav product
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
ES2327609T3 (es) 2000-06-01 2009-11-02 University Of North Carolina At Chapel Hill Procedimientos y compuestos para controlar la liberacion de vectores de parvovirus reconbinantes.
CA2406745C (en) 2001-11-13 2006-01-10 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
DK1453547T3 (en) 2001-12-17 2016-12-05 Univ Pennsylvania ADENOASSOCATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING THESE AND APPLICATIONS THEREOF
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
AU2004278684B2 (en) 2003-09-30 2011-05-12 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
CN112029737A (zh) 2005-04-07 2020-12-04 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
US9249425B2 (en) 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
US20210228739A1 (en) * 2018-05-15 2021-07-29 University Of Massachusetts Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a
SG11202103640VA (en) * 2018-10-10 2021-05-28 Amicus Therapeutics Inc Disulfide bond stabilized polypeptide compositions and methods of use
EP3890786A4 (en) * 2018-12-05 2022-08-31 Abeona Therapeutics Inc. RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR GENE RELEASE
CA3123598A1 (en) * 2018-12-20 2020-06-25 Codexis, Inc. Human alpha-galactosidase variants
SG11202107325TA (en) * 2019-01-04 2021-08-30 Sangamo Therapeutics Inc Methods and compositions for the treatment of fabry disease
CA3193833A1 (en) * 2020-10-09 2022-04-14 Juliette HORDEAUX Compositions and methods for treatment of fabry disease

Also Published As

Publication number Publication date
AU2022227017A1 (en) 2023-09-07
CN117321212A (zh) 2023-12-29
TW202302855A (zh) 2023-01-16
MX2023009978A (es) 2023-09-06
EP4298227A1 (en) 2024-01-03
CL2023002530A1 (es) 2024-04-19
BR112023016983A2 (pt) 2023-11-07
AR124981A1 (es) 2023-05-24
CA3209673A1 (en) 2022-09-01
WO2022183052A1 (en) 2022-09-01
CO2023011012A2 (es) 2023-08-28
JP2024509792A (ja) 2024-03-05
KR20230150836A (ko) 2023-10-31
US20240175054A1 (en) 2024-05-30
ECSP23072174A (es) 2023-10-31
IL305440A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
CL2022003757A1 (es) Vectores de aav que tienen una desamidación reducida de la cápside y sus usos (divisional solic 202002200).
PH12021551341A1 (en) Compositions for drg-specific reduction of transgene expression
MX2020008932A (es) Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
CL2020000295A1 (es) Métodos de terapia génica del factor viii (fviii)
PE20240806A1 (es) Composicion y metodos para el tratamiento de la enfermedad de fabry
ATE366319T1 (de) Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren
RU2018136611A (ru) Генная терапия для лечения гемофилии a
DE60115613D1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
MX2021005517A (es) Terapia genica para lipofuscinosis neuronal ceroidea.
AR118850A1 (es) Composiciones útiles en el tratamiento de leucodistrofia metacromática
MX2023001615A (es) Genoterapia con placofilina-2 (pkp2) mediante el uso de vector de aav.
MX2022009883A (es) Vectores de genoterapia para tratar enfermedades cardíacas.
WO2022173847A3 (en) Recombinant aavs with improved tropism and specificity
CL2009001249A1 (es) Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia.
WO2002063025A3 (en) Muscle-directed gene therapy with aav-1 and aav-6 vectors
CL2023001650A1 (es) Tratamiento de la enfermedad de danon
CL2023001876A1 (es) Proteínas de la cápside viral con especificidad para las células del tejido cardiaco
MX2022007135A (es) Vectores de virus adenoasociados para el tratamiento del síndrome de hunter.
MX2022014255A (es) Composiciones utiles para el tratamiento de la enfermedad de pompe.
PE20212072A1 (es) Composiciones utiles en el tratamiento de la enfermedad de krabbe
EA202191744A1 (ru) Композиции для drg-специфического снижения экспрессии трансгена
AR121245A1 (es) Composiciones útiles para tratar gangliosidosis gm1
CL2022002498A1 (es) Vectores de virus adenoasociado que tienen una desamidación reducida de la cápside (divisional solic 202002201).
MX2022014245A (es) Composiciones utiles en el tratamiento de la enfermedad de krabbe.
WO2023086928A3 (en) Gene therapy for treatment of mucopolysaccharidosis iiia